Telomir Pharmaceuticals, Inc. - Common Stock — Quarterly Financial Statistics (NASDAQ:TELO) | MetaTrader

Open full chart

Financials

Overview Statement Statistics Documents

Quarterly Annual

Cash from operating activities -863.13 K-696.44 K-927.26 K-1.2 M-1.77 M-1.01 M -4.91 M Cash from investing activities —————— — Cash from financing activities 01.05 M7.5 M1.16 M47.35 K622.11 K 9.33 M Free cash flow -863.13 K-696.44 K-927.26 K-1.2 M-1.77 M-1.01 M -4.91 M

News

Telo Genomics increases convertible debenture offering to $1.6M

Telo Genomics appoints John Price as new CFO

Rodman & Renshaw initiates Telomir Pharma stock with Buy rating

Coinbase CEO Brian Armstrong Says His Biotech Company Is Working On 'Extending' Human Lifespan: Here Is How They Plan To Do It

Telomir Pharmaceuticals sets CEO incentive awards and salary adjustment

Telomir reports PSA reduction in prostate cancer cells with lead drug

Telomir stock surges after leukemia cell-killing data

Telomir Pharmaceuticals director Craig Eagle resigns from board

Telomir-1 shows promise in modulating cancer defense genes

Telomir-1 shows efficacy against pancreatic cancer cells in lab study

Telomir Pharmaceuticals reports new preclinical data on pancreatic cancer

Why Is Telomir Pharmaceuticals Stock Trading Higher Today? - Telomir Pharmaceuticals (NASDAQ:TELO)